[Skip to Navigation]
Invited Commentary
November 18, 2021

Neuroprotective Therapies for Patients With Worsening Glaucoma Despite Adequate Intraocular Pressure Lowering—Short-term Neurorecovery, Long-term Neuroprotection?

Author Affiliations
  • 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Ophthalmol. 2022;140(1):18-19. doi:10.1001/jamaophthalmol.2021.4573

An important research focus in glaucoma has been to develop neuroprotective therapies for the subset of patients with glaucoma whose disease continues to worsen despite adequate intraocular pressure (IOP) lowering. While such patients represent a relatively modest fraction of those under care, they are a large proportion of our treatment failures. Additionally, these therapies, especially if easily available, cheap, and well tolerated, could be used as adjunct therapies to IOP lowering in patients at high risk of progression or with little functional reserve, such as those with advanced disease.

Add or change institution